4SC AG: Kathleen Masch-Wiest is new Member of the Management Board of 4SC

Planegg-Martinsried (pta006/14.11.2022/07:30) - Planegg-Martinsried, Germany, 14 November 2022 – The Supervisory Board of 4SC AG (4SC, FSE Prime Standard: VSC) has appointed Kathleen Masch-Wiest as a new member of the Management Board. Kathleen Masch-Wiest is a lawyer and has already worked for 4SC AG in the past as a member of the senior management, where she was responsible for Legal Affairs, Human Resources and Administration. She will continue to perform these tasks as COO in the future. Dr. Jason Loveridge, Chairman of the Management Board, welcomes Kathleen Masch-Wiest to the Management Board and looks forward to a trusting collaboration.

- Press release ends -

Further information

About 4SC

4SC AG ( http://www.4SC.com ) is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: resminostat ( http://www.4sc.com/product-pipeline/resminostat/ ).

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 20 employees as of 30 September 2022 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C40).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact

ir-pr@4sc.com
+49 89 700763-0

(Ende)